Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Quimbaya Gold Announces Upsize of Bought Deal Financing to $12.5 Million October 25, 2025 Torchlight Innovations Inc.Opens the Market October 25, 2025 Thor Energy Plans to Recover Uranium, Critical Minerals from Colorado Mine Waste October 25, 2025
